News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) And DSM Biologics Announce PER.C6 Licensing Agreement With JCR Pharmaceuticals For Protein Production


10/19/2005 5:12:59 PM

LEIDEN, The Netherlands, March 10, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6(R) research license agreement with leading Japanese pharmaceutical company JCR Pharmaceuticals Co., Ltd. This license agreement allows JCR to use the PER.C6(R) cell line for production of certain recombinant therapeutic proteins. Under the terms of the agreement, JCR will make a research license payment and annual maintenance fees. Further financial details were not disclosed.

Read at Prime Zone


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES